The University of Southampton
University of Southampton Institutional Repository

Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data

Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data
Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data

Objectives: to describe selected baseline characteristics, continuation with baricitinib and disease activity over time in patients initiating treatment with baricitinib in a UK real-world rheumatology setting.

Methods: baseline and follow-up data were analysed from baricitinib-treated patients newly recruited to the British Society for Rheumatology Biologics Registry-RA (BSRBR-RA) baricitinib cohort between 1 January 2018 and 31 March 2020. The primary objective was to evaluate continuation of baricitinib treatment in patients with at least one follow-up. Analyses were performed using the full baricitinib cohort, overall and by patient subgroup: biologic DMARD (bDMARD)/targeted synthetic (ts)DMARD-naive vs -experienced, baricitinib 4 vs 2 mg, age ≥65 vs <65 years, monotherapy vs combination therapy and male vs female.

Results: at baseline, the study cohort (n = 561) was 76.5% female, mean age 60.0 years, had longstanding (mean 13.1 years) and severe RA, and 54.0% had previously received a bDMARD/tsDMARD. Of 265 and 110 patients completing the 6- and 12-month follow-ups with available data, 77.7 and 69.1% remained on baricitinib at each time, respectively. In all Kaplan-Meier analyses, >60% of patients remained on baricitinib at 540 days. Continuation of baricitinib therapy differed between some subgroup pairs (bDMARD/tsDMARD naive/experienced, baricitinib 2 mg/4 mg). Disease activity was lower at both follow-ups than at baseline, overall and in all subgroups.

Conclusion: in the early years of real-world baricitinib use in the UK, a high proportion of patients continued with treatment at both 6 and 12 months, at which times disease activity was lower than at baseline.

Humans, Male, Female, Middle Aged, Aged, Arthritis, Rheumatoid/drug therapy, Biological Products/therapeutic use, Routinely Collected Health Data, Treatment Outcome, Antirheumatic Agents/therapeutic use, Biological Factors/therapeutic use
1462-0324
3400-3408
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106
Mount, Julie
c1e538be-9a36-4264-ad26-12552f10427f
Meeks, Alexandra
236c8717-13e6-4ba0-a21c-f4a3be112218
Gulati, Tania
7de5132a-7d67-41dc-aa39-911b016e1b07
Zaremba-Pechmann, Liliana
b1ed10f7-508e-49ee-b279-08e94f268ce5
Sheesh, Mohamed
d4a4bb56-7a5a-403c-9920-76dd50177e63
Larsson, Esbjörn
068be538-fa65-462b-be66-d656bba29f22
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106
Mount, Julie
c1e538be-9a36-4264-ad26-12552f10427f
Meeks, Alexandra
236c8717-13e6-4ba0-a21c-f4a3be112218
Gulati, Tania
7de5132a-7d67-41dc-aa39-911b016e1b07
Zaremba-Pechmann, Liliana
b1ed10f7-508e-49ee-b279-08e94f268ce5
Sheesh, Mohamed
d4a4bb56-7a5a-403c-9920-76dd50177e63
Larsson, Esbjörn
068be538-fa65-462b-be66-d656bba29f22
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1

Edwards, Christopher J., Mount, Julie, Meeks, Alexandra, Gulati, Tania, Zaremba-Pechmann, Liliana, Sheesh, Mohamed, Larsson, Esbjörn and Dennison, Elaine (2023) Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data. Rheumatology (Oxford, England), 62 (10), 3400-3408. (doi:10.1093/rheumatology/kead074).

Record type: Article

Abstract

Objectives: to describe selected baseline characteristics, continuation with baricitinib and disease activity over time in patients initiating treatment with baricitinib in a UK real-world rheumatology setting.

Methods: baseline and follow-up data were analysed from baricitinib-treated patients newly recruited to the British Society for Rheumatology Biologics Registry-RA (BSRBR-RA) baricitinib cohort between 1 January 2018 and 31 March 2020. The primary objective was to evaluate continuation of baricitinib treatment in patients with at least one follow-up. Analyses were performed using the full baricitinib cohort, overall and by patient subgroup: biologic DMARD (bDMARD)/targeted synthetic (ts)DMARD-naive vs -experienced, baricitinib 4 vs 2 mg, age ≥65 vs <65 years, monotherapy vs combination therapy and male vs female.

Results: at baseline, the study cohort (n = 561) was 76.5% female, mean age 60.0 years, had longstanding (mean 13.1 years) and severe RA, and 54.0% had previously received a bDMARD/tsDMARD. Of 265 and 110 patients completing the 6- and 12-month follow-ups with available data, 77.7 and 69.1% remained on baricitinib at each time, respectively. In all Kaplan-Meier analyses, >60% of patients remained on baricitinib at 540 days. Continuation of baricitinib therapy differed between some subgroup pairs (bDMARD/tsDMARD naive/experienced, baricitinib 2 mg/4 mg). Disease activity was lower at both follow-ups than at baseline, overall and in all subgroups.

Conclusion: in the early years of real-world baricitinib use in the UK, a high proportion of patients continued with treatment at both 6 and 12 months, at which times disease activity was lower than at baseline.

Text
kead074 - Version of Record
Download (483kB)

More information

Accepted/In Press date: 5 February 2023
e-pub ahead of print date: 24 February 2023
Published date: 3 October 2023
Keywords: Humans, Male, Female, Middle Aged, Aged, Arthritis, Rheumatoid/drug therapy, Biological Products/therapeutic use, Routinely Collected Health Data, Treatment Outcome, Antirheumatic Agents/therapeutic use, Biological Factors/therapeutic use

Identifiers

Local EPrints ID: 487347
URI: http://eprints.soton.ac.uk/id/eprint/487347
ISSN: 1462-0324
PURE UUID: 0d62f65c-4f1e-4c65-893b-7fa94863ffdc
ORCID for Elaine Dennison: ORCID iD orcid.org/0000-0002-3048-4961

Catalogue record

Date deposited: 19 Feb 2024 20:27
Last modified: 18 Mar 2024 02:42

Export record

Altmetrics

Contributors

Author: Julie Mount
Author: Alexandra Meeks
Author: Tania Gulati
Author: Liliana Zaremba-Pechmann
Author: Mohamed Sheesh
Author: Esbjörn Larsson
Author: Elaine Dennison ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×